VolitionRx Limited Opens its New Manufacturing Facility in Belgium
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes,Belgium. Vol...
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately$4 million from the Walloon Region and Namur Invest,Belgium. To date, Agencies from the Walloon Region have a...
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the...
Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the l...
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr.Mark Eccleston, a founding sci...
VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update
* Launch of first product, the Nu.Q™ Vet Cancer Screening Test planned for November 30, 2020 * Engaged Diagnostic Oncology CRO LLC to conduct U.S. clinical trial for Non-Hodgkin's Lymphoma * Expanded research program for the use of Nu.Q™ technology in NETosis AUSTIN, Texas, Nov. 12, 2020 /P...
Volition Veterinary Presents Expert Report Ahead of First Product Launch
* A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts * Report provides insight into the clinical impact of early cancer detection, and recent advances * Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guid...
VolitionRx Limited Schedules Third Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, November 13, at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter 2020, in addition to providing a b...
VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 21, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital ma...
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will host a capital...
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further d...
Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference
AUSTIN, Oct. 12, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will present two abstract...
VolitionRx Limited Announces Virtual Capital Markets Day 2020
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, today announced it will host a capital market...
VolitionRx Limited to Present at Conferences in September 2020
AUSTIN, Texas, Sept. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at five conferences inSeptember 2020. ...
VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update
AUSTIN, Texas, August 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter endedJune 30, 2020. Volition management will host a conference call tomorrow,August 14 at 8:30 a.m. U.S. Eastern Time...
VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, August 14, at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020, in addition to providing a b...
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from...
VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited
Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer,Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group. Event Det...
